Malaria – Pipeline Review, H2 2020

Global Markets Direct’s, ‘Malaria – Pipeline Review, H2 2020’, provides an overview of the Malaria pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Malaria, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Malaria and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Malaria

– The report reviews pipeline therapeutics for Malaria by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Malaria therapeutics and enlists all their major and minor projects

– The report assesses Malaria therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Malaria

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Malaria

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Malaria pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

4SC AG

60 Degrees Pharmaceuticals LLC

AbbVie Inc

AchilleS Vaccines Srl

Akshaya Bio Inc

Alfasigma SpA

AliquantumRx Inc

Allergy Therapeutics Plc

Altimmune Inc

Artemis Therapeutics Inc

Artificial Cell Technologies Inc

AUM LifeTech Inc

Avalia Immunotherapies Ltd

Bharat Biotech Ltd

Brain-Gen LLC

Bristol-Myers Squibb Co

Cadila Healthcare Ltd

Carna Biosciences Inc

Cascade Therapeutics Inc

Cellics Therapeutics Inc

Cesa Alliance SA

Cilian AG

Collaborations Pharmaceuticals Inc

Curevac AG

DesignMedix Inc

DMG Deutsche Malaria GmbH

Eisai Co Ltd

ElSohly Laboratories Inc

EpicentRx Inc

EpiVax Inc

Etna Biotech Srl

Evotec SE

Expres2ion Biotechnologies ApS

Fox Chase Chemical Diversity Center Inc

GeoVax Labs Inc

GlaxoSmithKline Plc

Hawaii Biotech Inc

Ichor Medical Systems Inc

Immtech Pharmaceuticals Inc

Immune Modulation Inc

Imutex Ltd

IMV Inc

Indoco Remedies Ltd

Innovex Therapeutics SL

IPCA Laboratories Ltd

Jacobus Pharmaceutical Co Inc

Kainomyx Inc

Kymab Ltd

LondonPharma Ltd

Lumen Bioscience Inc

Lyndra Therapeutics Inc.

MedinCell SA

MediSynergics LLC

MegaNano BioTech Inc

Merck & Co Inc

Merck KGaA

Microbiotix Inc

Mitsubishi Tanabe Pharma Corp

Mycosynthetix Inc

Mymetics Corp

Nobelpharma Co Ltd

Novartis AG

Ocean Biomedical

Osivax SAS

Otsuka Holdings Co Ltd

Pacific Meniuoke Biopharmaceutical Company

Pfizer Inc

Protein Potential LLC

Radix Pharmaceuticals Inc

Replikins Ltd

Rodos BioTarget GmbH

Sanaria Inc

Sanofi

Serum Institute of India Ltd

Shanghai Fosun Pharmaceutical (Group) Co Ltd

Shin Poong Pharm Co Ltd

Sumaya Biotech GmbH & Co KG

Sumitomo Dainippon Pharma Co Ltd

Takeda Pharmaceutical Co Ltd

Theravectys SA

Titan Pharmaceuticals Inc

Vac4All SAS

VLP Biotech Inc

VLP Therapeutics LLC

Table of Contents

Table of Contents

Introduction

Malaria- Overview

Malaria- Therapeutics Development

Malaria- Therapeutics Assessment

Malaria- Companies Involved in Therapeutics Development

Malaria- Drug Profiles

Malaria- Dormant Projects

Malaria- Discontinued Products

Malaria- Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Malaria, H2 2020

Number of Products under Development by Companies, H2 2020

Number of Products under Development by Universities/Institutes, H2 2020

Products under Development by Companies, H2 2020

Products under Development by Universities/Institutes, H2 2020

Number of Products by Stage and Target, H2 2020

Number of Products by Stage and Mechanism of Action, H2 2020

Number of Products by Stage and Route of Administration, H2 2020

Number of Products by Stage and Molecule Type, H2 2020

Malaria – Pipeline by 4SC AG, H2 2020

Malaria – Pipeline by 60 Degrees Pharmaceuticals LLC, H2 2020

Malaria – Pipeline by AbbVie Inc, H2 2020

Malaria – Pipeline by AchilleS Vaccines Srl, H2 2020

Malaria – Pipeline by Akshaya Bio Inc, H2 2020

Malaria – Pipeline by Alfasigma SpA, H2 2020

Malaria – Pipeline by AliquantumRx Inc, H2 2020

Malaria – Pipeline by Allergy Therapeutics Plc, H2 2020

Malaria – Pipeline by Altimmune Inc, H2 2020

Malaria – Pipeline by Artemis Therapeutics Inc, H2 2020

Malaria – Pipeline by Artificial Cell Technologies Inc, H2 2020

Malaria – Pipeline by AUM LifeTech Inc, H2 2020

Malaria – Pipeline by Avalia Immunotherapies Ltd, H2 2020

Malaria – Pipeline by Bharat Biotech Ltd, H2 2020

Malaria – Pipeline by Brain-Gen LLC, H2 2020

Malaria – Pipeline by Bristol-Myers Squibb Co, H2 2020

Malaria – Pipeline by Cadila Healthcare Ltd, H2 2020

Malaria – Pipeline by Carna Biosciences Inc, H2 2020

Malaria – Pipeline by Cascade Therapeutics Inc, H2 2020

Malaria – Pipeline by Cellics Therapeutics Inc, H2 2020

Malaria – Pipeline by Cesa Alliance SA, H2 2020

Malaria – Pipeline by Cilian AG, H2 2020

Malaria – Pipeline by Collaborations Pharmaceuticals Inc, H2 2020

Malaria – Pipeline by Curevac AG, H2 2020

Malaria – Pipeline by DesignMedix Inc, H2 2020

Malaria – Pipeline by DMG Deutsche Malaria GmbH, H2 2020

Malaria – Pipeline by Eisai Co Ltd, H2 2020

Malaria – Pipeline by ElSohly Laboratories Inc, H2 2020

Malaria – Pipeline by EpicentRx Inc, H2 2020

Malaria – Pipeline by EpiVax Inc, H2 2020

Malaria – Pipeline by Etna Biotech Srl, H2 2020

Malaria – Pipeline by Evotec SE, H2 2020

Malaria – Pipeline by Expres2ion Biotechnologies ApS, H2 2020

Malaria – Pipeline by Fox Chase Chemical Diversity Center Inc, H2 2020

Malaria – Dormant Projects, H2 2020

Malaria – Discontinued Products, H2 2020

List of Figures

List of Figures

Number of Products under Development for Malaria, H2 2020

Number of Products under Development by Companies, H2 2020

Number of Products under Development by Universities/Institutes, H2 2020

Number of Products by Top 10 Targets, H2 2020

Number of Products by Stage and Top 10 Targets, H2 2020

Number of Products by Top 10 Mechanism of Actions, H2 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020

Number of Products by Top 10 Routes of Administration, H2 2020

Number of Products by Stage and Top 10 Routes of Administration, H2 2020

Number of Products by Top 10 Molecule Types, H2 2020

Number of Products by Stage and Top 10 Molecule Types, H2 2020

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports